Navigation Links
Pioneer(R) Surgical Technology Announces First Human Implants of New nanOss(TM)-Cervical Fusion Device
Date:10/16/2008

First Synthetic Nanotechnology Implant Offers Promising Patient Solutions

MARQUETTE, Mich., Oct. 16 /PRNewswire/ -- Pioneer Surgical Technology, Inc., a leader in innovative medical devices, announced today the successful human implantation of its new biologic inter-body spacer. The nanOss(TM)- Cervical cage is machined from mechanically robust nano-crystalline hydroxyapatite (HA) and is designed to function as bone. The surgeries were performed at hospitals in Beijing and Suzhou, China, on patients indicated for standard cervical fusion surgery using the nanOss(TM)-Cervical implant, bone graft material, and anterior cervical plate.

Dr. Hansen Yuan, Professor of Orthopaedic and Neurological Surgery, State University of New York Upstate Medical University, Syracuse, NY performed the surgeries with Chinese surgeons and says, "The nanOss-Cervical cage was handled and implanted similarly to PEEK (poly-ether-ether-ketone) cages, and was used in conjunction with routine rigid fixation. The benefit of nanOss technology to the patient is it is a safe, natural substance and is biocompatible."

Pioneer's nanOss-Cervical cage is intended to facilitate spinal fusion procedures, by simultaneously maintaining decompression and serving as a graft containment device in conjunction with traditional rigid fixation.

Pioneer's CEO and Chairman of the Board, Dr. Matthew N. Songer says, "The hydroxyapatite nanOss-Cervical design is the frontier of the new generation of biologic implants that will replace the foreign materials that are currently used to reconstruct the spine."

In less than a year from acquiring the nanOss technology, Pioneer's development teams have created the nanOss-Cervical cage for fusion procedures. Strength properties of materials made of nanOss technology are twice as strong as PEEK cages yet, being biologic, behave as if it were bone.

About Pioneer Surgical Technology

Pioneer(R) Surgical Technology, Inc. is a dynamic medical device firm founded in 1992. Pioneer's focus on innovation has resulted in over 100 U.S. and Foreign patents with numerous patents pending." The company's comprehensive portfolio of CE or investigational motion preservation devices, vertebral spacers, cervical plating systems, and MIS and Mini-Open Rod systems include notable trade names such as NuBac(TM), BacJac(TM), Contact(TM), IJAK(R), Clarity(TM), SlimFuse(TM), and Quantum(R). Pioneer entered the orthobiologics market with two acquisitions in 2007. Encelle(TM), Inc., developed E-Matrix(TM) for tissue regeneration. Angstrom(TM) Medica, Inc. is the first company to obtain FDA approval for a nanotechnology device -- nanOss(TM) -- hydroxyapatite bone void filler. Pioneer's Orthopaedic, Spine, and Biologic divisions produce state of the art, cost-effective solutions for surgical procedures that have proven difficult or problematic for both surgeons and patients. Pioneer employs more than 260 people worldwide.


'/>"/>
SOURCE Pioneer Surgical Technology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pioneer(R) Surgical Technology Announces Market Release of FortrOss(TM), a Next Generation Bone Void Filler
2. DuPont Obtains Biotechnology Endorsement for Pioneer(R) Brand Products
3. Pioneer(R) Surgical Technology, Inc. Announces the Market Launch of the SlimFuse(TM) Anterior Cervical Plate System
4. Pioneer(R) Brand Soybeans From DuPont Deliver Step-Change in Soybean Yields
5. Pioneer(R) Surgical Technology Announces First Human Implants of its NuNec(TM) Cervical Arthroplasty Device
6. DuPont Congratulates Growers Planting Pioneer(R) Brand Sorghum Hybrids in Winning Majority of National Categories in Yield Contest
7. CryoLife Hosts Worldwide Surgical Congress for the Ross Procedure
8. Reliant Technologies Announces FDA 510(K) Clearance of New Handpieces for Skin Resurfacing and Surgical Applications
9. New Opportunities in X-Ray Based Surgical Navigation With Ziehm NaviPort 3D
10. Sound Surgical Technologies Welcomes Dr. Mark Schafer as New Chief Technology Officer and Vice President of Research & Development
11. Solos Endoscopy, Inc. Implements Strategy to Capitalize on $30 Billion Minimally Invasive Surgical Product Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... -- Fluxion Biosciences announced today that Genetracer Biotech of ... as a Certified Service Provider for Fluxion,s IsoFlux CTC ... in Genetracer Biotech,s novel liquid biopsy workflows for detection ... plans to move to other cancers as additional assays ... to isolate, recover, and analyze CTCs (circulating tumor cells) ...
(Date:2/25/2017)... Garden City, New York (PRWEB) , ... February ... ... announced their partnership with Verified Clinical Trials in an ongoing effort ... the areas of treatment, advocacy, and pharmaceutical research with emphasis on consumers and ...
(Date:2/24/2017)... 24, 2017 Provectus Biopharmaceuticals, Inc. (OTCQB: ... a clinical-stage oncology and dermatology biopharmaceutical company, today ... participate in its previously announced rights offering of ... of common stock and Series C Convertible Preferred ... warrants. As previously announced, the ...
(Date:2/24/2017)... -- China Cord Blood Corporation (NYSE: CO ... cord blood collection, laboratory testing, hematopoietic stem cell processing ... financial results for the third quarter and first nine ... Third Quarter of Fiscal 2017 Highlights ... 2017 increased by 18.6% to RMB200.9 million ($28.9 million). ...
Breaking Biology Technology:
(Date:2/21/2017)... and PORTLAND, Ore. , Feb. 22, ... Avamere Family of Companies (Avamere Health Services, Infinity Rehab, ... six-month research study that will apply the power of ... senior living and health centers. By analyzing data streaming ... gain insights into physical and environmental conditions, and obtain ...
(Date:2/13/2017)... Former 9/11 Commission border counsel and Special ... Kephart of Identity Strategy Partners, LLP, today releases ... "Executive Order: Protecting the Nation From Foreign Terrorist Entry ... "As President Trump,s ,Travel Ban, Executive Order gains more ... the travel ban, it is important that our national ...
(Date:2/8/2017)... YORK , Feb. 7, 2017 Report Highlights ... The ... should reach $11.4 billion by 2021, growing at a compound ... Includes - An overview of the global markets for synthetic ... 2015, estimates for 2016, and projections of compound annual growth ...
Breaking Biology News(10 mins):